Clinical Trials
Tracker

Healing & Recovery

Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway.

Metabolic / GLP-1 Agonist

FDA-approved (Ozempic for T2D, Wegovy for obesity)

Metabolic / Dual GIP-GLP-1 Agonist

FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA)

Sexual Health

FDA-approved (Vyleesi for HSDD in premenopausal women)

Growth Hormone Secretagogue

Research-only / Not approved for human use

Growth Hormone Secretagogue

Research-only / Not approved for human use

Melanocortin Agonist

Research-only / Not approved. Multiple regulatory warnings issued worldwide.

Growth Hormone Secretagogue

Previously FDA-approved (Geref, discontinued); now used off-label via compounding

Growth Hormone Secretagogue

FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy

Growth Hormone Secretagogue

Research-only / Not approved for human use

Growth Hormone Secretagogue

Approved in Japan for GH deficiency diagnosis; research-only elsewhere

Anti-Aging / Telomere

Research-only / No approved human indication in Western countries

Immune Modulator

Approved in 35+ countries (Zadaxin); FDA orphan drug designation; not FDA-approved in the US

Nootropic / Anxiolytic

Approved in Russia as an anxiolytic nasal spray; not approved elsewhere

Nootropic / Neuroprotective

Approved in Russia and Ukraine for stroke and cognitive disorders; not approved elsewhere

Sleep / Neuropeptide

Research-only / Not approved for any indication

Growth Hormone Secretagogue

Multiple Phase II trials completed. Not FDA-approved. Investigational.

Reproductive / Hormonal

FDA-approved (Factrel for diagnostic use; Lutrepulse for pulsatile infertility treatment, now discontinued). Generic diagnostic formulation available.

Metabolic / Mitochondrial

FDA-approved (Forzinity, September 2025) for Barth syndrome. Phase II (heart failure, renal dysfunction, age-related macular degeneration).

Nootropic / Neuroprotective

Approved as prescription drug in 50+ countries (Austria, Russia, China, South Korea, and others). Not FDA-approved. Over 150 clinical trials with >7,000 patients.

Metabolic / GLP-1 Agonist

FDA-approved (Victoza for T2D, Saxenda for obesity)

Tissue Repair / Neuropathic Pain

Phase II clinical trials completed for sarcoidosis neuropathy, diabetic neuropathy, and corneal nerve repair. FDA Orphan Drug Designation granted. Not yet approved.

Metabolic / GLP-1 Agonist

FDA-approved (Byetta for T2D, 2005; Bydureon for T2D, 2012)

Metabolic / GLP-1 Agonist

FDA-approved (Trulicity for T2D, September 2014; cardiovascular risk reduction, 2020)

Metabolic / GLP-1 Agonist

FDA-approved (Adlyxin for T2D, July 2016; Soliqua 100/33 combination, November 2016)

Metabolic / GLP-1 Agonist

Previously FDA-approved (Tanzeum for T2D, April 2014). Voluntarily withdrawn from market July 2018 (commercial reasons, not safety).

Metabolic / Amylin Analog

FDA-approved (Symlin for T1D and T2D as adjunct to mealtime insulin, March 2005)

Metabolic / Endogenous Hormone

Endogenous hormone. Not itself used as a drug. Serves as the basis for pramlintide (Symlin, FDA-approved) and cagrilintide (investigational).

Metabolic / Bone Health

FDA-approved (Miacalcin injection 1986; Miacalcin nasal spray 1995; Fortical nasal spray 2005). Used for osteoporosis, Paget disease, and hypercalcemia.

Metabolic / MC4R Agonist

FDA-approved (Imcivree, November 2020 for POMC/PCSK1/LEPR deficiency obesity; June 2022 for BBS obesity)

Metabolic / Dual GLP-1/Glucagon Agonist

Approved in China (June 2024) for chronic weight management. Phase III in China for T2D. Not yet approved outside China.

Reproductive / Hormonal

FDA-approved (Pitocin for labor induction, augmentation of labor, and postpartum hemorrhage)

Reproductive / Hormonal

FDA-approved (Vasostrict for vasodilatory shock in adults)

Reproductive / Hormonal

FDA-approved (DDAVP for central diabetes insipidus, hemophilia A, type 1 von Willebrand disease, primary nocturnal enuresis)

Reproductive / Hormonal

FDA-approved (Terlivaz for hepatorenal syndrome type 1, September 2022)

Reproductive / Hormonal

WHO Essential Medicine. Approved in over 30 countries for PPH prevention following cesarean section. Not FDA-approved in the United States.

Reproductive / Hormonal

FDA-approved (Lupron Depot for prostate cancer, endometriosis, uterine fibroids, central precocious puberty; Eligard for prostate cancer; Fensolvi for central precocious puberty)

Reproductive / Hormonal

FDA-approved (Zoladex for prostate cancer, breast cancer, endometriosis, endometrial thinning)

Reproductive / Hormonal

FDA-approved (Trelstar for advanced prostate cancer; Triptodur for central precocious puberty)

Reproductive / Hormonal

FDA-approved (Synarel for endometriosis and central precocious puberty)

Reproductive / Hormonal

FDA-approved (Vantas for advanced prostate cancer; Supprelin LA for central precocious puberty)

Reproductive / Hormonal

FDA-approved (Firmagon for advanced prostate cancer, December 2008)

Reproductive / Hormonal

FDA-approved (Ganirelix Acetate Injection for prevention of premature LH surges in IVF, 1999)

Reproductive / Hormonal

FDA-approved (Cetrotide for prevention of premature LH surges in IVF)

Reproductive / Hormonal

Approved in EU, Canada, Australia, and other markets for prostate cancer, endometriosis, and IVF protocols. Not FDA-approved in the United States.

Growth Hormone Secretagogue

FDA-approved (December 2017) as a diagnostic test for adult GH deficiency.

Hormone

FDA-approved for multiple indications. First approved in 1985 (recombinant form).

Growth Factor

FDA-approved (Increlex/mecasermin) for severe primary IGF-1 deficiency.

Growth Factor / Cosmetic

Approved for wound healing in some countries (South Korea, Cuba). Used as a cosmetic ingredient globally.

Immune Modulator

Investigational. Small clinical studies in immunodeficiency and aging; no approved therapeutic indication.

Antimicrobial / Immune

Preclinical. Bee venom therapy (apitherapy) is used in traditional medicine. No approved pharmaceutical product based on isolated melittin.

Antimicrobial / Immune

Phase III completed. Two NDA submissions to FDA (1999 and 2016) — both unsuccessful. Not approved in any jurisdiction.

Antimicrobial / Immune

Phase III completed for catheter infections (not approved, 2003). Phase III for rosacea (CLS001 by Cutanea Life Sciences, results ~2018). No regulatory approval.

Nootropic / Cognitive

Approved in Russia for cognitive disorders. Not evaluated by FDA, EMA, or other Western regulatory agencies. Clinical trial data primarily in Russian-language literature.

Neuropeptide / Reference

Endogenous neuropeptide. Not a drug. NK1R antagonists (aprepitant, fosaprepitant, netupitant) are FDA-approved antiemetics. NK1R antagonists for depression showed mixed clinical results.

Neuropeptide / Reference

Endogenous neuropeptide. Not a drug. NPY receptor agonists and antagonists have been investigated for obesity, anxiety, and epilepsy but none are approved.

Neuropeptide / Reference

Aviptadil (synthetic VIP) received FDA Emergency Use Authorization consideration for COVID-19 ARDS. Phase II/III trials for ARDS completed. Not FDA-approved for any indication. Investigational for pulmonary hypertension and sarcoidosis.

Cardiovascular / Vasoactive

FDA-approved (Giapreza, December 2017) for vasodilatory shock in adults

Cardiovascular / Vasoactive

Preclinical and early-phase research. No approved therapeutic indication.

Cardiovascular / Natriuretic

FDA-approved (Natrecor, August 2001) for acute decompensated heart failure. Use declined significantly after ASCEND-HF trial (2011) showed no mortality benefit.

Cardiovascular / Natriuretic

Carperitide (recombinant hANP) approved in Japan (1995) for acute heart failure. Not approved in the US, EU, or other Western markets.

Cardiovascular / Natriuretic

Established diagnostic biomarker for heart failure. Recombinant form (nesiritide) is FDA-approved for acute decompensated heart failure.

Cardiovascular / Vasoactive

Reference peptide. Not used therapeutically. Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) are FDA-approved for pulmonary arterial hypertension.

Cardiovascular / Vasoactive

Preclinical and early-phase clinical investigation. No approved therapeutic indication.

Cardiovascular / Vasoactive

Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide.

Endocrine / Somatostatin Analog

FDA-approved (Sandostatin 1988; Sandostatin LAR 1998)

Endocrine / Somatostatin Analog

FDA-approved (Somatuline Depot for acromegaly 2007; GEP-NETs 2014)

Endocrine / Somatostatin Analog

FDA-approved (Signifor SC for Cushing disease, 2012; Signifor LAR for acromegaly, 2014)

Metabolic / Pancreatic Hormone

FDA-approved (emergency hypoglycemia treatment; GI diagnostic aid)

Gastrointestinal / GLP-2 Analog

FDA-approved (Gattex for SBS, December 2012)

Gastrointestinal / GC-C Agonist

FDA-approved (Trulance for CIC, January 2017; IBS-C, January 2018)

Gastrointestinal / GC-C Agonist

FDA-approved (Linzess for IBS-C and CIC, August 2012)

Bone / PTH Analog

FDA-approved (Tymlos for postmenopausal osteoporosis, April 2017)

Bone / PTH Analog

FDA-approved (Forteo for osteoporosis, November 2002)

Bone / Calcitonin

FDA-approved (Miacalcin nasal spray and injection; Fortical nasal spray)

Bone / PTH Analog

FDA-approved (Natpara for hypoparathyroidism, 2015; voluntary recall 2019 due to device issue; returned to market)

Melanocortin Agonist

FDA-approved (Scenesse for EPP, October 2019); EMA-approved (2014)

Sexual Health

FDA-approved (Vyleesi for premenopausal HSDD, June 2019)

Pain / Kappa-Opioid Agonist

FDA-approved (Korsuva for CKD-associated pruritus in hemodialysis patients, August 2021)

Pain / Calcium Channel Blocker

FDA-approved (Prialt for severe chronic pain via intrathecal infusion, December 2004)

Hematology / TPO Agonist

FDA-approved (Nplate for chronic ITP, August 2008)

Antiviral / HIV

FDA-approved (Fuzeon for HIV-1 infection in treatment-experienced patients, March 2003)

Rare Disease / Bradykinin Antagonist

FDA-approved (Firazyr for acute HAE attacks, August 2011)

Cardiovascular / Antiplatelet

FDA-approved (Integrilin for ACS/PCI, 1998)

Cardiovascular / Antithrombotic

FDA-approved (Angiomax for PCI anticoagulation, 2000)

Cardiovascular / Antithrombotic

FDA-approved (Iprivask for DVT prophylaxis post hip replacement, 2003)

Hormonal / Reproductive

FDA-approved for anovulation/infertility, hypogonadotropic hypogonadism, prepubertal cryptorchidism.

Metabolic / Fat Oxidation

FDA-approved (IV, for carnitine deficiency). SC injection widely used off-label for metabolic optimization.

Growth Hormone

FDA-approved (multiple indications). Numerous brand-name products available worldwide.

Immune / Anti-Aging

Approved medication in Russia for immunodeficiency. Used clinically since 1982. Western clinical evidence is limited.

Dermatology / Approved

FDA-approved (2019) and EMA-approved (2014) for EPP

Nootropic / Anxiolytic

Research-only (base form approved in Russia)

Neuroendocrine / Approved (diagnostic)

FDA-approved as diagnostic agent (Protirelin)

Immune / Bioregulator

Research-only (approved in Russia)

Pain & Analgesia

Research compound only. No approved human indication. Banned in competitive horse racing.

Growth Hormone

FDA-approved for multiple indications. Extensive clinical data spanning decades.

Satiety / Metabolic

Well-characterized endogenous hormone. Infusion studies in humans completed. No approved PYY-based drug.

GI / Metabolic

Preclinical as a therapeutic. GC-C agonist drugs (linaclotide, plecanatide) are FDA-approved for IBS-C and chronic constipation.

Pain / Migraine

Endogenous peptide. Anti-CGRP therapies are FDA-approved for migraine prevention and treatment. CGRP itself is not a therapeutic.

Immune Modulator / Bioregulator

Approved in Russia for clinical use. No Western regulatory approval. Very limited English-language evidence.

Growth Hormone Secretagogue

Approved in Japan (2021) for cancer cachexia. Phase III trials completed (ROMANA 1 & 2). Not FDA/EMA approved.

Weight Loss / GLP-1 Agonist

Phase 2 completed (REDEFINE 1). Phase 3 expected 2026. Investigational — not approved anywhere.

Growth Hormone / Appetite

Endogenous hormone. Analog anamorelin approved in Japan for cancer cachexia. Multiple analogs in clinical trials.

Metabolic / Weight Loss

Endogenous hormone. Multiple analogs FDA-approved: semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide (dual GIP/GLP-1).

Reproductive / Neurological

Approved in some countries for labor induction and lactation support. Used off-label for anxiolytic and pro-social effects.

Reproductive / Hormone Support

FDA-approved (Menopur) for controlled ovarian stimulation and hypogonadotropic hypogonadism.

Growth Hormone

Research compound. Phase 1/2 clinical data exists (ConjuChem). Not approved for any indication.